When two well-known consumer names line up for their public debut in the same week, the market naturally leans in. That’s exactly what’s happening with the Wakefit IPO and the Corona Remedies IPO, both gearing up to open for subscription next week. The timing, the scale, the buzz — it all adds up to a busy stretch for the primary market.
As someone who tracks market sentiment daily at Samco Securities, I’ve watched how investors respond when large consumer and healthcare players step into the IPO lane. The story is usually simple: strong brands draw strong attention. And this time, the narrative feels no different.
Let’s walk through each IPO with clean, structured details — short paragraphs, crisp transitions, and data that speaks for itself.
Wakefit IPO: A Consumer Brand Moving Into the Public Market
Wakefit Innovations has become a recognized name in the home and furnishings space. And now the company is ready to make its first appearance on the public markets with a sizeable offering.
The Wakefit IPO aims to raise ₹1,289 crore through its maiden public issue. Subscription for the offer will open on December 8 and close on December 10. The company has set a price band of ₹185–₹195 per share, valuing Wakefit at nearly ₹6,400 crore.
The allocation to anchor investors is planned for December 5, and the listing is expected on December 15.
For a brand that became a household name through digital-first strategies, mattresses, and furniture, the IPO marks an important milestone. Wakefit’s move into the listed space reflects its shift from a direct-to-consumer journey to broader institutional visibility.
Corona Remedies IPO: Healthcare Player Enters the Market
On the other side of the market, Corona Remedies, a pharma company backed by ChrysCapital, is also stepping into the spotlight next week.
The company has lined up a ₹655.37 crore IPO, with a price band of ₹1,008–₹1,062 per share. The issue will open on December 8 and close on December 10, mirroring Wakefit’s subscription window. Corona Remedies is also scheduled to list on December 15.
For a company operating in the chronic therapy and specialty medicine space, the IPO marks a new chapter that aligns with the broader growth seen across the healthcare sector in recent years.
Why These Two IPOs Matter This Week?
Both Wakefit and Corona Remedies tap into different corners of the economy — consumer lifestyle and pharmaceuticals. Yet, their arrival in the same week creates a combined moment for the IPO market.
Here’s what stands out:
- Two major sectors — consumption and healthcare
- Two sizeable issues opening on the same dates
- Both scheduled for December 15 listing
- Clean, straightforward financial structures
- Well-known brand presence in their respective industries
This blend often drives interest among retail investors who track new listings closely, especially when household brands step forward.
Company Snapshot: Quick Details at a Glance
To make the information easier to parse, here are the core numbers side-by-side — no extra commentary, just clean details:
Wakefit IPO
- Issue Size: ₹1,289 crore
- Price Band: ₹185–₹195 per share
- Subscription Window: Dec 8–10
- Anchor Allocation: Dec 5
- Listing Date: Dec 15
- Approx. Valuation: ₹6,400 crore
Corona Remedies IPO
- Issue Size: ₹655.37 crore
- Price Band: ₹1,008–₹1,062 per share
- Subscription Window: Dec 8–10
- Listing Date: Dec 15
- Investor Backing: ChrysCapital
Summary: A Busy Week Ahead for IPO Investors
Next week brings two important IPOs — Wakefit in consumer furnishings and Corona Remedies in pharmaceuticals. Each brings a strong brand presence, clear financial details, and a subscription window that runs in parallel.
Both issues land on the market from December 8–10, and both are slated to list on December 15. With the home, furniture, and healthcare sectors all in focus, the week is shaping up to be one of the most active phases in the December primary market calendar.
Easy & quick
Leave A Comment?